Pain And Function Are Best Endpoints For Knee Cartilage Trials – FDA Panel
By
Ingrid Mezo / Email the Author / “The Gray Sheet” Jun. 15, 2009, Vol. 35, No. 024
Regulatory / Word Count: 334 / Article # 01350240011
Executive Summary
Joint pain and function are the most clinically meaningful efficacy outcomes and should both be used as primary endpoints for clinical trials of cellular products for treatment of knee cartilage defects, FDA's Cellular, Tissue and Gene Therapies Advisory Committee recommends
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.